Fluorine-18-THK 5351

Drug Profile

Fluorine-18-THK 5351

Alternative Names: [18F]THK-5351; F-18 THK-5351; FluoroTau; GE-216

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tohoku University
  • Developer Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; GE Healthcare; Tohoku University
  • Class Antidementias; Imaging agents; Pyridines; Quinolines; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Neurodegenerative disorders
  • Clinical Phase Unknown Aphasia; Lewy body disease; Mild cognitive impairment; Progressive supranuclear palsy

Most Recent Events

  • 13 Feb 2018 Chang Gung Memorial Hospital plans a phase II trial for Major depressive disorder (Diagnosis) in March 2018 , (NCT03430869)
  • 10 Oct 2017 Phase-II clinical trials in Neurodegenerative disorders (Diagnosis) in Spain (IV) (EudraCT2015-004656-22)
  • 24 Aug 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top